z-logo
Premium
Prescribing patterns of tricyclic and selective serotonin reuptake inhibitor antidepressants among a sample of adolescents and young adults
Author(s) -
Kairuz Therèse,
Truter Ilse,
Hugo Johan,
Foxcroft Cheryl
Publication year - 2003
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.854
Subject(s) - fluoxetine , medicine , tricyclic , antidepressant , tricyclic antidepressant , pharmacoepidemiology , serotonin reuptake inhibitor , reuptake inhibitor , psychiatry , serotonin , pharmacology , medical prescription , anxiety , receptor
Purpose There are few studies that document antidepressant prescribing in young patients. Although tricyclic antidepressants (TCAs) are considered equal in efficacy to selective serotonin reuptake inhibitors (SSRIs), the latter have an improved side effect profile. The aim of this study was to investigate the prescribing patterns of TCAs and SSRIs among adolescents and young adults, with reference to prescribing frequency, cost and dose. Method A retrospective drug utilization study was conducted over a 14‐month period, from January 2000 to February 2001. Results There were 166 antidepressants prescribed to 98 adolescents and young adults. TCAs were prescribed more frequently than SSRIs, with amitryptiline and fluoxetine being the two most frequently prescribed antidepressants. Fluoxetine accounted for a higher ratio of cost to prescribing frequency than amitryptiline. Amitryptiline was issued in small quantities of tablets, resulting in a low average calculated prescribed daily dose (PDD). Duration of treatment was not considered optimal for SSRIs or TCAs. Conclusion This study elicits prescribing patterns that contribute to the relative scarcity of data on antidepressant drugs for young patients. Copyright © 2003 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here